Vaxcyte, Inc.는 임상 개발 단계에 있는 생명공학 기업으로, 혁신적인 단백질 기반 백신을 만드는 데 전념하고 있습니다. 회사의 주요 목적은 세균성 감염 질환을 ...
예상 EPS $-2.12 · 매출 $12.50M · 4 명의 애널리스트
예상 EPS $-2.07 · 매출 $12.50M · 4 명의 애널리스트
예상 EPS $-8.21 · 매출 $25.00M · 6 명의 애널리스트
예상 EPS $-1.21 · 매출 $0.00 · 1 명의 애널리스트
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $0 | — | — |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-766.6M | -65.2% | +11.3% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | — | — | — |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | — | — | — |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | — | — | — |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-669.3M | -40.9% | -80.2% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | — | — | — |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 8.5% | +296.1% | +7.8% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 7.91x | -38.0% | -23.6% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $3.0B | -13.3% | -6.3% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -5.63 vs -5.44 | -3.5% | -1.97 vs -2.06 | +4.2% |
| 매출 서프라이즈 | — | — | $0 vs $12.5M | -100.0% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Wassil Jim | officer: CHIEF OPERATING OFFICER | Common Stock | D | 1,432 | $61.58 |
| Sep 2, 2026 | PICKERING GRANT | director, officer: CHIEF EXECUTIVE OFFICER | Common Stock | D | 3,427 | $61.58 |
| Sep 2, 2026 | GUGGENHIME ANDREW | officer: PRESIDENT AND CFO | Common Stock | D | 1,432 | $61.58 |
| Sep 2, 2026 | Dhaliwal Harpreet S. | officer: Chief Technical Ops Officer | Common Stock | D | 659 | $61.58 |
| Sep 2, 2026 | Cowan Elvia | officer: SVP, Finance & CAO | Common Stock | D | 326 | $61.58 |
Operator: Good afternoon. My name is Chloe, and I will be your conference operator for the Vaxcyte Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] Today's call is being recorded. I will now turn the call over to Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. Please go ahead, sir. Andrew Guggenhime: Thank you, operator. Good afternoon, everyone, and thanks for joining us today as we review our 2025 results and provide a business update. I am joined by our Chief Executive Officer, Grant Pickering; and our Executive Vice President and Chief Operating Officer, Jim Wassil. Earlier today, we issued a news release announcing our results. Copies of this and our other news releases, latest corporate presentation and SEC filings can be found in the Investors and Media section of our website. Before we begin, I'd like to remind you that during this call, we'll be making certain forward-looking statements about Vaxcyte, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with these statements, please see our press release issued today as well as our most recent filings with the SEC, including the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and any subsequent reports filed with the SEC. With that, I'll turn the call over to Grant Pickering. Grant? Grant Pickering: Thanks, Andrew. As we close out 2025 and look forward to multiple clinical readouts beginning later this year, I'm proud of the progress we made across the company, particularly within our pneumococcal conjugate vaccine or PCV franchise. Despite decades of vaccination efforts, pneumococcal disease continues to drive substantial morbidity and mortality worldwide, particularly among young children and older adults. While current vaccines have made a meaningful impact, gaps in serotype coverage persist and the public health need for broader spectrum protection remains clear. Consistent with that need, we are seeing accelerating growth in the adult PCV market, driven by expanded age group recommendations in the United States and increasing international adoption of adult PCV vaccination. Continued momentum in the PCV class has reinforced the size of the opportunity and demand for a PCV that increases disease coverage by protecting against both historically and currently circulating serotypes while maintaining robust immune responses. Taken together, this underscores our opportunity to improve public health as we prepare to enter an increasingly attractive commercial market. The unprecedented results from our Phase II study in adults demonstrated that VAX-31 may offer substantial improvement over existing products and achieve our objective to significantly expand disease coverage while maintaining high immunogenicity …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Grant E. Pickering | 공동 창립자, 최고경영자(CEO) & 이사 | USD 1,444,730 | Male | 1968 | Active |
Andrew L. Guggenhime | 사장 & 최고재무책임자(CFO) | USD 960,230 | Male | 1968 | Active |
Mikhail Eydelman | 수석 부사장, 법무총괄(General Counsel), 최고준법책임자 & 사무국장 | USD 752,712 | Male | 1982 | Active |
Harp Dhaliwal | 최고기술운영책임자(CTOO) | USD 743,618 | Male | 1973 | Active |
James Wassil | 전무이사 부사장 & 최고운영책임자(COO) | USD 614,730 | Male | 1969 | Active |
Whitney Jones | 최고인사책임자(CPO) | — | Female | — | Active |
Elvia Cowan | 재무 부문 수석 부사장(VP) & 최고회계책임자(CAO) | — | Female | 1973 | Active |
Janet Graesser | 기업 대외업무 수석 부사장 | — | Female | — | Active |
Jeff Fairman | 공동 창립자 & 연구 부문 부사장 | — | — | 1964 | Active |
Jeff Macdonald | 투자자 관계(Investor Relations) 전무이사 | — | Male | — | Active |
Assenagon Asset Management S.A. reduced its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 91.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 101,433 shares of the company's stock after selling 1,063,380 shares during the period. Assenagon Asset Management S.A. owned 0.07% of Vaxcyte
Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027 Approximately $2.5 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026 SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
Shares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) have been given an average rating of "Hold" by the nine analysts that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company.
Bank of New York Mellon Corp lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 5.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 474,526 shares of the company's stock after purchasing an additional 25,163
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:
